Skip to main content

Capital Markets Day

Watch the replay of the Capital Markets Day 2024.

Capital Markets Day Fresenius Helios

June 05, 2024
London, UK

Capital Markets Day Fresenius Helios

More information


"Fresenius has made an excellent start into the year and our focus on Fresenius Kabi and Fresenius Helios is paying off. We are confident to maintain our growth momentum and raise our outlook for the full year. With the exit from Vamed, our strategic portfolio restructuring is completed as planned. Fresenius is already a simpler, stronger, and more innovative company due to the consistent implementation of #FutureFresenius. We now have even more opportunities to offer world-class therapies and improve people’s health."

Michael Sen, Chairman of the Management Board

Financial Highlights Q1/24

Group Revenue

5704 m

+6% 1, 2, 3

Q1/23: €5,546 m

Group EBIT 4

633 m

+15% 3, 5, 6

Q1/23: €554 m

Net income 4, 7

429 m

+11% 3, 5

Q1/23: €389 m

KABI Revenue

2051 m

+9% 1, 2

Q1/23: €1,991m

HELIOS Revenue

3184 m

+5% 1, 3

Q1/23: €3,066 m

Vamed Revenue

561 m

1% 1

Q1/23: €583 m

1 Organic revenue growth

2 Organic growth rate adjusted for accounting effects related to Argentina hyperinflation

3 Adjusted for the divestment of the Eugin group and the hospital in Peru

4 Before special items

5 At constant currency

6 Growth rates adjusted to Argentina hyperinflation

7 Net income attributable to shareholders of Fresenius SE & Co. KGaA